Tang Mo, Zhang Wei, Qin Wenyu, Zou Chao, Yan Yunzi, He Bin, Xu Yun, Zhang Ying, Liu Jianping, Sun Hong, Yang Yufei
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Beijing Cancer Hospital, Beijing 100142, China.
Evid Based Complement Alternat Med. 2022 Nov 8;2022:8529395. doi: 10.1155/2022/8529395. eCollection 2022.
To evaluate the associations between long-term oral Chinese herbal medicines (CHMs) and recurrence and metastasis (R&M) in patients with stage II and III colorectal cancer (CRC). Furthermore, we aimed to determine the correlation between different syndrome patterns and prognosis and summarized the regularities among CHMs prescriptions, providing reference for clinical practice.
An ambispective cohort study was conducted. All CRC patients who sought evaluation and treatment at Xiyuan Hospital and Beijing Cancer Hospital from August 2014 to August 2016 were included. In this study, "whether patients voluntarily take CHMs" was taken as the exposure factor, and the exposure degree was "the duration of CHM use." Stratification was performed according to the duration of TCM use to determine the relationship with R&M of CRC. The primary outcome was disease-free survival. Patients who had R&M of CRC after taking CHMs for ≥6 months were defined as "worst patients." software was used for statistical analysis. The Kaplan-Meier method and Cox regression analysis were used to determine the prognosis. IBM SPSS was used to model a priori association rules; drug use rules were analyzed on this basis.
A total of 186 patients with stage II and III CRC after radical resection were enrolled. All patients reached the study endpoint by August 2021. The difference in disease-free survival between the two groups was most significant when the cutoff value for CHMs was 18 months ( = 0.0012). Multivariate analysis showed that 18 CHMs were independent protective factors for R&M of CRC ( = 0.001, HR = 0.20, 95% CI = 0.08-0.53). The ratio of Pi (spleen) and Shen (kidney) deficiency in the worst cases was higher than patients without R&M ( = 0.018). Sijunzi and Liuwei Dihuang decoctions were the most frequently used prescriptions in the anti-R&M phase.
CHMs complying with the "Jianpi Bushen" principle may attenuate the risk of R&M in patients with stage II and III CRC. Pi (spleen) and Shen (kidney) deficiency in patients receiving TCM intervention for the first time within 6 months of radical resection may be associated with a higher CRC R&M rate. Further research is warranted to validate these findings and elucidate underlying biological mechanisms.
评估长期口服中药与Ⅱ、Ⅲ期结直肠癌(CRC)患者复发转移(R&M)之间的关联。此外,我们旨在确定不同证型与预后之间的相关性,并总结中药方剂规律,为临床实践提供参考。
进行一项回顾性队列研究。纳入2014年8月至2016年8月期间在西苑医院和北京肿瘤医院寻求评估和治疗的所有CRC患者。在本研究中,将“患者是否自愿服用中药”作为暴露因素,暴露程度为“服用中药的时长”。根据服用中药的时长进行分层,以确定其与CRC复发转移的关系。主要结局为无病生存期。服用中药≥6个月后发生CRC复发转移的患者被定义为“最差患者”。使用软件进行统计分析。采用Kaplan-Meier法和Cox回归分析来确定预后。使用IBM SPSS对先验关联规则进行建模;在此基础上分析用药规律。
共纳入186例Ⅱ、Ⅲ期CRC根治性切除术后患者。截至2021年8月,所有患者均达到研究终点。当服用中药的截断值为18个月时,两组无病生存期差异最为显著(P = 0.0012)。多因素分析显示,18味中药是CRC复发转移的独立保护因素(P = 0.001,HR = 0.20,95%CI = 0.08 - 0.53)。最差患者中脾虚和肾虚的比例高于无复发转移患者(P = 0.018)。四君子汤和六味地黄丸是抗复发转移阶段最常用的方剂。
符合“健脾补肾”原则的中药可能降低Ⅱ、Ⅲ期CRC患者复发转移的风险。根治性切除术后6个月内首次接受中医干预的患者脾虚和肾虚可能与较高的CRC复发转移率相关。有必要进一步研究以验证这些发现并阐明潜在的生物学机制。